Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) and Neurogene (NASDAQ:NGNE – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.
Valuation & Earnings
This table compares Foghorn Therapeutics and Neurogene”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Foghorn Therapeutics | $30.91 million | 4.02 | -$74.28 million | ($0.98) | -2.13 |
| Neurogene | $930,000.00 | 620.09 | -$90.35 million | ($5.03) | -5.73 |
Foghorn Therapeutics has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
61.5% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 9.0% of Foghorn Therapeutics shares are held by insiders. Comparatively, 11.7% of Neurogene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings for Foghorn Therapeutics and Neurogene, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Foghorn Therapeutics | 1 | 6 | 4 | 0 | 2.27 |
| Neurogene | 1 | 0 | 5 | 2 | 3.00 |
Foghorn Therapeutics currently has a consensus target price of $6.14, indicating a potential upside of 193.92%. Neurogene has a consensus target price of $80.29, indicating a potential upside of 178.58%. Given Foghorn Therapeutics’ higher probable upside, equities research analysts clearly believe Foghorn Therapeutics is more favorable than Neurogene.
Profitability
This table compares Foghorn Therapeutics and Neurogene’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Foghorn Therapeutics | -175.78% | N/A | -31.17% |
| Neurogene | N/A | -45.10% | -41.00% |
Risk and Volatility
Foghorn Therapeutics has a beta of 3.01, meaning that its share price is 201% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.
Summary
Foghorn Therapeutics beats Neurogene on 8 of the 14 factors compared between the two stocks.
About Foghorn Therapeutics
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
About Neurogene
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
Receive News & Ratings for Foghorn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foghorn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
